Overview of the biopharmaceutical moieties, developed with technology from the Protein Technologies consortium, in (pre)clinical development or marketed.

F4+ ETEC targeting VHH & IgA-Fc -fusion antibody 

An oral feed-based passive immunization strategy against a pathogen (ETEC) causing post-weaning infections in young piglets. Technology built on the cross-disciplinary research and expertise within the labs of Henri De Greve (VIB/VUB), Ann De Picker (VIB/UGent) and Nico Callewaert (VIB/UGent) as well as the lab of Eric Cox from the veterinary faculty of UGent.  Read all about it in the 2019 Nature Biotechnology paper.


Enzybiotics are a new breed of antimicrobials. They can be functionally optimized using a modular design- and synthesis approach. The VersaTile platform uses this specific approach for neofunctionalization of proteins to create other, new biopharmaceutical molecules. Read more in this Science Advances paper.



The lab of Xavier Saelens (VIB-UGent Center for Medical Biotechnology) has announced the isolation and characterization of a unique antibody that can bind to the virus that causes COVID-19 (SARS-CoV-2). The team has established that the antibody binds to the spike protein of SARS-CoV-2. Importantly, the antibody can neutralize a lab variant of the virus. Their work appears in Cell. The researchers are also developing a mouse model for assessing COVID-19 antibody and vaccine candidates. In 2020, a spin-off company, Exevir, was created to further develop a therapeutic antibody against SARS-CoV-2.